Tenderwize
Back to tender search

Non-exclusive rebate agreement for interferon beta-1a injection

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Apr 30, 2028 · 617 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Interferon beta-1a zur subkutanen Injektion (ATC-Code nach WHO: L03AB07)

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

62 / 100

Complexity

58 / 100

Risk factors

The notice says participation documents are to be submitted via the DTVP communication function, while also stating tha...

Eligibility is limited to pharmaceutical companies under Section 4(18) AMG for the offered product, and Russia-sanction...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Conclusion of non-exclusive rebate agreements under Section 130a(8) SGB V for pharmaceutical products with active substance interferon beta-1a for subcutaneous injection.
  • Open-house participation model with no individual negotiations and no supply exclusivity.
Show full summary

Open-house framework-style supply arrangement for non-exclusive pharmaceutical rebate agreements for interferon beta-1a for subcutaneous injection (CPV 33600000) led by AOK PLUS. The procedure is open to all eligible pharmaceutical companies during the participation period, with no individual negotiations and no exclusivity. Submission is electronic via DTVP communication functions, but the notice says the portal’s bidding tool is not used for submission in this open-house process. The contract runs until 30 April 2028 at the latest; no contract value is stated and minimum purchase volumes are not guaranteed.

Risks

The notice says participation documents are to be submitted via the DTVP communication function, while also stating tha...

Eligibility is limited to pharmaceutical companies under Section 4(18) AMG for the offered product, and Russia-sanction...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Applicant must be a pharmaceutical company within the meaning of Section 4(18) AMG for the offered medicinal product.
  • The company or its participating entity must not have a Russia-related link within the meaning of Article 5k of Regulation (EU) No 833/2014 as amended.

Eligibility

  • The self-declaration on the absence of exclusion grounds must be completed and submitted with the participation documents.

Buyer

Location

Erfurt, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive rebate agreement for interferon beta-1a injection

Single lot covering the conclusion of non-exclusive pharmaceutical rebate agreements for medicines containing interferon beta-1a for subcutaneous injection. The lot is an open-house model, so any interested eligible pharmaceutical company may participate during the participation period. No exclusivity, no individual negotiations, and no guaranteed minimum purchase quantities are stated. Place of performance is Dresden, Germany.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Apr 2026 - Apr 2028

Category

Pharmaceutical products

Deadline

Deadline Apr 30, 2028

Procurement Details

Publication date
04 Mar 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
155288-2026

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3